TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for a European safety study of dupilumab and other systemic therapies in patients with atopic eczema
暂无分享,去创建一个
L. Naldi | C. Flohr | J. Schmitt | A. Manca | J. Thyssen | D. Prieto-Merino | T. Torres | Å. Svensson | B. Arents | S. Barbarot | S. Weidinger | A. Irvine | C. Vestergaard | M. Deleuran | P. Spuls | L. Eichenfield | I. García-Doval | J. Seneschal | L. Kobyletzki | C. Apfelbacher | A. Roberts | P. Mendes-Bastos | D. Wall | A. Bosma | M. Middelkamp-Hup | L. Gerbens | F. Vermeulen | F. Tesch | E. Baselga | L. V. Kobyletzki | P. Spuls | Jochen Schmitt | David Prieto-Merino | Åke Svensson | Alan D. Irvine | J. P. Thyssen | Luigi Naldi | Ignacio García-Doval | Christian Apfelbacher | Sébastien Barbarot | Eulalia Baselga | Andrea Manca | Amanda Roberts | J. Seneschal | Tiago Torres | C. Flohr | C. Apfelbacher | S. Barbarot | T. Torres | L. Naldi
[1] J. Giovannelli,et al. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort. , 2019, Journal of the American Academy of Dermatology.
[2] C. Flohr,et al. TREatment of ATopic eczema (TREAT) Registry Taskforce: consensus on how and when to measure the core dataset for atopic eczema treatment research registries , 2019, The British journal of dermatology.
[3] C. Flohr,et al. TREatment of ATopic eczema (TREAT) Registry Taskforce: an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema photo‐ and systemic therapy registries , 2018, The British journal of dermatology.
[4] I. Pavord,et al. Dupilumab Efficacy and Safety in Moderate‐to‐Severe Uncontrolled Asthma , 2018, The New England journal of medicine.
[5] C. Flohr,et al. The International TREatment of ATopic Eczema (TREAT) Registry Taskforce: An Initiative to Harmonize Data Collection across National Atopic Eczema Photo- and Systemic Therapy Registries. , 2017, The Journal of investigative dermatology.
[6] G. Yancopoulos,et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial , 2017, The Lancet.
[7] C. Flohr,et al. Treatment of moderate‐to‐severe atopic eczema in adults within the U.K.: results of a national survey of dermatologists , 2017, The British journal of dermatology.
[8] C. Flohr,et al. TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for an international Delphi exercise to identify a core set of domains and domain items for national atopic eczema registries , 2017, Trials.
[9] J. Silverberg,et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. , 2016, The New England journal of medicine.
[10] E. R. Sutherland,et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial , 2016, The Lancet.
[11] J. Vandenbroucke,et al. Point: Incident Exposures, Prevalent Exposures, and Causal Inference: Does Limiting Studies to Persons Who Are Followed From First Exposure Onward Damage Epidemiology? , 2015, American journal of epidemiology.
[12] P. Spuls,et al. Ten years experience with oral immunosuppressive treatment in adult patients with atopic dermatitis in two academic centres , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.
[13] S. Feldman,et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. , 2014, Journal of the American Academy of Dermatology.
[14] J. Schmitt,et al. Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review. , 2014, The Journal of allergy and clinical immunology.
[15] K. Schmiegelow,et al. Use of azathioprine and the risk of cancer in inflammatory bowel disease. , 2013, American journal of epidemiology.
[16] M. El-Khalawany,et al. Methotrexate versus cyclosporine in the treatment of severe atopic dermatitis in children: a multicenter experience from Egypt , 2013, European Journal of Pediatrics.
[17] B. Fingleton,et al. Cytokine stimulation of epithelial cancer cells: the similar and divergent functions of IL-4 and IL-13. , 2012, Cancer research.
[18] J. Ring,et al. Guidelines for treatment of atopic eczema (atopic dermatitis) Part II , 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.
[19] J. Ring,et al. Guidelines for treatment of atopic eczema (atopic dermatitis) Part I , 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.
[20] C. Flohr,et al. The European treatment of severe atopic eczema in children taskforce (TREAT) survey , 2012, The British journal of dermatology.
[21] F. Vanaclocha,et al. Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials. , 2012, Archives of dermatology.
[22] R. Agans,et al. Systemic Treatment of Pediatric Atopic Dermatitis with Azathioprine and Mycophenolate Mofetil , 2011, Pediatric dermatology.
[23] R. Schlienger,et al. Incidence of cancer in the general population and in patients with or without atopic dermatitis in the U.K. , 2010, The British journal of dermatology.
[24] Zhiguang Li,et al. Paradoxical Roles of IL-4 in Tumor Immunity , 2009, Cellular and Molecular Immunology.
[25] C. Chow,et al. Efficacy and tolerability at 3 and 6 months following use of azathioprine for recalcitrant atopic dermatitis in children and young adults , 2009, The Journal of dermatological treatment.
[26] Sylvie Chevret,et al. Sample size formula for proportional hazards modelling of competing risks , 2004, Statistics in medicine.
[27] D. Atherton,et al. A retrospective evaluation of azathioprine in severe childhood atopic eczema, using thiopurine methyltransferase levels to exclude patients at high risk of myelosuppression , 2002, The British journal of dermatology.
[28] A. Finlay,et al. Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy , 2000, The British journal of dermatology.
[29] P. Krupp,et al. The risk of neoplasms in patients treated with cyclosporine A. , 1989, Journal of autoimmunity.
[30] D. Macdonald,et al. Skin cancer and cyclosporine therapy. , 1985, The New England journal of medicine.
[31] J. Thompson,et al. Hypertrichosis and Multiple Cutaneous Squamous Cell Carcinomas in Association with Cyclosporin a Therapy 1 , 1983, Journal of the Royal Society of Medicine.
[32] D. Schoenfeld,et al. Sample-size formula for the proportional-hazards regression model. , 1983, Biometrics.
[33] K. Kragballe,et al. Methotrexate induced liver cirrhosis , 1980, The British journal of dermatology.
[34] W. Tom,et al. Oral azathioprine for recalcitrant pediatric atopic dermatitis: clinical response and thiopurine monitoring. , 2013, Journal of the American Academy of Dermatology.
[35] K. Schäkel,et al. Systemic treatment of severe atopic eczema: a systematic review. , 2007, Acta dermato-venereologica.
[36] I I Lelis,et al. [Atopic dermatitis]. , 1980, Vestnik dermatologii i venerologii.